Development of human endogenous retrovirus type K- related treatments for human diseases.
Lu DaiJiaojiao FanZhiqiang QinPublished in: Journal of medical virology (2024)
Human endogenous retroviruses (HERVs) constitute approximately 8% of the human genome and have long been regarded as silent passengers within our genomes. However, the reactivation of HERVs has been increasingly linked to a range of human diseases, particularly the HERV-K (HML-2) family. Many studies are dedicated to elucidating the potential role of HERV-K in pathogenicity. While the underlying mechanisms require further investigation, targeting HERV-K transactivation emerges as a promising avenue for treating human diseases, including cancer, autoimmune disorders, neurodegenerative conditions, and infectious diseases. In this review, we summarize recent advancements in the development of HERV-K-targeted therapeutic strategies against various human diseases, including antiretroviral drugs, immunotherapy, and vaccines.
Keyphrases
- endothelial cells
- induced pluripotent stem cells
- pluripotent stem cells
- gene expression
- escherichia coli
- squamous cell carcinoma
- multiple sclerosis
- infectious diseases
- human immunodeficiency virus
- hepatitis c virus
- cystic fibrosis
- papillary thyroid
- south africa
- genome wide
- cancer therapy
- hiv aids
- men who have sex with men
- hiv infected patients